Perspective Therapeutics, Inc.
CATX
$2.16
-$0.03-1.37%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -43.36% | -44.87% | 5.23% | -30.56% | 33.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.36% | -44.87% | 5.23% | -30.56% | 33.70% |
| Cost of Revenue | 69.10% | 79.19% | 86.88% | 74.64% | 116.64% |
| Gross Profit | -72.66% | -86.65% | -90.75% | -80.78% | -120.98% |
| SG&A Expenses | 10.84% | 39.81% | 33.41% | 66.92% | 55.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.71% | 64.51% | 66.35% | 75.56% | 89.54% |
| Operating Income | -49.52% | -68.54% | -67.87% | -78.62% | -91.12% |
| Income Before Tax | -71.73% | -96.17% | -53.72% | -262.51% | -57.98% |
| Income Tax Expenses | -- | -- | -- | -126.72% | -- |
| Earnings from Continuing Operations | -71.73% | -96.17% | -53.72% | -105.78% | -57.98% |
| Earnings from Discontinued Operations | -- | 204.90% | -- | 98.86% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.73% | -83.57% | -47.97% | -62.79% | -46.02% |
| EBIT | -49.52% | -68.54% | -67.87% | -78.62% | -91.12% |
| EBITDA | -50.77% | -70.23% | -66.81% | -252.44% | -89.66% |
| EPS Basic | -63.24% | -64.81% | -1.25% | 35.44% | 41.99% |
| Normalized Basic EPS | -63.30% | -76.05% | -5.16% | 38.21% | 37.24% |
| EPS Diluted | -63.24% | -64.81% | -1.25% | -29.56% | 41.99% |
| Normalized Diluted EPS | -63.30% | -76.05% | -5.16% | 38.21% | 37.24% |
| Average Basic Shares Outstanding | 5.19% | 11.38% | 46.15% | 152.15% | 151.75% |
| Average Diluted Shares Outstanding | 5.19% | 11.38% | 46.15% | 152.15% | 151.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |